NImmune Biopharma has entered a research partnership with BioTherapeutics, aimed at propelling the development of new precision medicines in the field of inflammation and immunology.
The deal will enhance NImmune’s capabilities in precision immunology by leveraging BioTherapeutics’ extensive preclinical services and regulatory expertise.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
NImmune will benefit from BioTherapeutics’ animal models, including pig models for inflammatory bowel disease, pharmacokinetics/pharmacodynamics analysis capabilities and specialised regulatory infrastructure for product testing.
The deal will also aid in mechanism of action validation studies and the development of both animal and computational models of autoimmune and inflammatory diseases.
BioTherapeutics chief scientific officer Dr Raquel Hontecillas stated: “We are excited to collaborate across teams in support of the development of much-needed therapeutics by providing our highly sophisticated computational and preclinical services, including our proprietary efficacy animal models of autoimmune and inflammatory disease.
“The unique drug development ecosystem created here in Blacksburg enables and equips our organisations to develop safer and more effective therapeutics at an increasingly efficient and accelerated pace.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe partnership with BioTherapeutics adds to NImmune’s existing research and development (R&D) collaboration with the NIMML Institute.
Together, they will form a scientific innovation ecosystem that enables transdisciplinary teams to collaborate from discovery through various development phases.
This ecosystem has already yielded significant clinical and commercial success, as evidenced by the development of NX-13 and its subsequent acquisition by AbbVie.
NImmune founder and CEO Dr Josep Bassaganya-Riera stated: “The collaboration with BioTherapeutics is a crucial extension of NImmune’s innovative R&D ecosystem that is enabling our team to create safer and more effective immunoregulatory therapeutics that address the unmet clinical needs of patients with inflammatory and autoimmune diseases.
“Through NImmune’s strategic partnerships with both the NIMML Institute and BioTherapeutics, we have created a best-in-class scientific ecosystem capable of accelerating the pipeline — from AI-enabled target discovery and validation using the TITAN-X platform to preclinical animal modelling to clinical testing and ultimately commercialisation.”
